Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 5/20 | 0.55 |
| ▸ | CSNK2B | P67870 | 5/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TERT | O14746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL909776 | 0.87 | PIK3CD (0.54) | CSNK2A2CSNK2BCSNK2A1CYP3A4CYSLTR1 | |
| SCHEMBL910340 | 0.85 | CYP1A1 (0.54) | CSNK2A2CSNK2BCSNK2A1CYP3A4MAPT | |
| SCHEMBL910042 | 0.79 | CYP1A1 (0.54) | CSNK2A2CSNK2BCSNK2A1CYSLTR1CYP1B1 | |
| SCHEMBL12835506 | 0.79 | CYP3A4 (0.52) | CSNK2A2CSNK2BCSNK2A1CYP3A4HPGD | |
| SCHEMBL30928765 | 0.78 | BRD4 (0.44) | CSNK2A2CSNK2BCSNK2A1CYSLTR1CYP1B1 | |
| SCHEMBL909722 | 0.78 | CSNK2A2 (0.49) | CSNK2A2CSNK2BCSNK2A1CYSLTR1CYP1B1 | |
| SCHEMBL31115275 | 0.78 | CSNK2A2 (0.52) | CSNK2A2CSNK2BCSNK2A1ALDH1A1CYSLTR1 | |
| SCHEMBL24912981 | 0.77 | ALDH1A1 (0.50) | CSNK2A2CSNK2BCSNK2A1CYP3A4HPGD | |
| SCHEMBL24912684 | 0.77 | PIK3CD (0.60) | CSNK2A2CSNK2BCSNK2A1CYP3A4HPGD | |
| SCHEMBL25185013 | 0.76 | PIK3CA (0.39) | KDM4ECYSLTR1MEN1KMT2APRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873295-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873295-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PETRA PHARMA CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230017140-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873295-B2 | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease | PIK3CA, PIK3R4, PIK3R5 | CSNK2A2 276/4885CSNK2B 234/4885CSNK2A1 188/4885 |
| US-20230017140-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | CSNK2A2 276/4885CSNK2B 234/4885CSNK2A1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.